Systemic Actions of SGLT2 Inhibition on Chronic mTOR Activation as a Shared Pathogenic Mechanism between Alzheimer’s Disease and Diabetes

• Published in: Biomedicines Vol. 9; no. 5; p. 576
• Main Authors: Stanciu, Gabriela Dumitrita, Rusu, Razvan Nicolae, Bild, Veronica, Filipiuc, Leontina Elena, Tamba, Bogdan-Ionel, Ababei, Daniela Carmen
• Format: Journal Article
• Language: English
• Published: Basel MDPI AG 19-05-2021; MDPI
• Subjects: Adenosine triphosphate; Aging; Alzheimer's disease; Autophagy; Blood-brain barrier; Brain research; Diabetes; Diabetes mellitus; Glucose; Homeostasis; Hypotheses; mechanistic target of rapamycin; metabolic dysfunction hypothesis; Metabolic syndrome; Mitochondria; Molecular modelling; Morphology; Neurodegenerative diseases; Oxidative stress; Pathogenesis; Phosphorylation; Proteins; Rapamycin; Review; Senile plaques; sodium glucose cotransporter 2 inhibition; Tau protein; TOR protein
• ISSN: 2227-9059; 2227-9059
• DOI: 10.3390/biomedicines9050576

Alzheimer’s disease (AD) affects tens of millions of people worldwide. Despite the advances in understanding the disease, there is an increased urgency for pharmacological approaches able of impacting its onset and progression. With a multifactorial nature, high incidence and prevalence in later years of life, there is growing evidence highlighting a relationship between metabolic dysfunction related to diabetes and subject’s susceptibility to develop AD. The link seems so solid that sometimes AD and type 3 diabetes are used interchangeably. A candidate for a shared pathogenic mechanism linking these conditions is chronically-activated mechanistic target of rapamycin (mTOR). Chronic activation of unrestrained mTOR could be responsible for sustaining metabolic dysfunction that causes the breakdown of the blood-brain barrier, tau hyperphosphorylation and senile plaques formation in AD. It has been suggested that inhibition of sodium glucose cotransporter 2 (SGLT2) mediated by constant glucose loss, may restore mTOR cycle via nutrient-driven, preventing or even decreasing the AD progression. Currently, there is an unmet need for further research insight into molecular mechanisms that drive the onset and AD advancement as well as an increase in efforts to expand the testing of potential therapeutic strategies aimed to counteract disease progression in order to structure effective therapies.